| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea73c2e84003ad40f945c93b9b055e0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9d88bc99d45a6ff557121ecf0988d73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_606fd60f22dd25c2d7dd7b2a0480597b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3d03cb288b448e454c4958daed30fe8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate |
2010-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d240e9fbf423a5f31444f2198914d6a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_526c29769ce50e827a2de208b4835aac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31e4c121b5af799ebf6f8d2ac37e5c81 |
| publicationDate |
2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012122798-A1 |
| titleOfInvention |
Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| abstract |
Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an ammo acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009016959-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980892-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016213760-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3307326-A4 |
| priorityDate |
2009-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |